Stock 300254 SHANXI C&Y PHARMACEUTICAL GROUP CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials ShanXi C&Y Pharmaceutical Group Co.,LTD.

Equities

300254

CNE1000016D0

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 14/05/2024 BST 		5-day change 1st Jan Change
9.29 CNY -1.90% Intraday chart for ShanXi C&Y Pharmaceutical Group Co.,LTD. -8.20% -3.53%
04-12 ShanXi C&Y Pharmaceutical Group Co.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-18 ShanXi C&Y Pharmaceutical Group Co.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,350 1,689 1,571 1,981 1,636 2,327
Enterprise Value (EV) 1 1,490 1,894 1,688 2,103 1,661 2,461
P/E ratio 216 x 319 x -5.6 x -21.7 x -13.5 x 92.3 x
Yield 0.31% - - - - -
Capitalization / Revenue 1.19 x 1.49 x 1.85 x 2.13 x 1.97 x 2.91 x
EV / Revenue 1.31 x 1.67 x 1.99 x 2.26 x 2 x 3.08 x
EV / EBITDA 15.8 x 84.5 x -12.5 x 60.4 x 48.7 x 31.9 x
EV / FCF -75.4 x -106 x 100 x 90.8 x 5.25 x -12.2 x
FCF Yield -1.33% -0.94% 1% 1.1% 19.1% -8.2%
Price to Book 1.69 x 2.07 x 2.29 x 3.36 x 2.85 x 3.88 x
Nbr of stocks (in thousands) 208,308 208,308 227,971 227,971 241,619 241,619
Reference price 2 6.480 8.110 6.890 8.690 6.770 9.630
Announcement Date 26/04/19 27/04/20 26/04/21 28/04/22 24/04/23 18/03/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,136 1,132 848.1 930.4 829 799.3
EBITDA 1 94.14 22.41 -135.4 34.84 34.08 77.24
EBIT 1 39.69 -28.12 -198.3 -28.16 -23.64 25.1
Operating Margin 3.49% -2.48% -23.39% -3.03% -2.85% 3.14%
Earnings before Tax (EBT) 1 14.77 1.894 -298.4 -65.48 -90.02 55.28
Net income 1 7.241 5.297 -262.4 -91.44 -118.6 25.2
Net margin 0.64% 0.47% -30.94% -9.83% -14.3% 3.15%
EPS 2 0.0300 0.0254 -1.230 -0.4011 -0.5002 0.1043
Free Cash Flow 1 -19.75 -17.79 16.84 23.16 316.6 -201.7
FCF margin -1.74% -1.57% 1.99% 2.49% 38.19% -25.24%
FCF Conversion (EBITDA) - - - 66.46% 929.01% -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 0.0200 - - - - -
Announcement Date 26/04/19 27/04/20 26/04/21 28/04/22 24/04/23 18/03/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 140 204 118 122 25 135
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.488 x 9.118 x -0.8677 x 3.511 x 0.7327 x 1.742 x
Free Cash Flow 1 -19.8 -17.8 16.8 23.2 317 -202
ROE (net income / shareholders' equity) 1.03% -0.19% -31.1% -9.22% -13.3% 6.46%
ROA (Net income/ Total Assets) 1.65% -1.07% -6.88% -1.06% -0.95% 1.04%
Assets 1 440 -497 3,813 8,642 12,484 2,423
Book Value Per Share 2 3.840 3.920 3.010 2.590 2.380 2.480
Cash Flow per Share 2 0.7100 0.6900 0.8300 0.4700 1.090 0.5500
Capex 1 29.6 18.5 31.5 36.9 26.8 33.9
Capex / Sales 2.6% 1.64% 3.71% 3.97% 3.23% 4.24%
Announcement Date 26/04/19 27/04/20 26/04/21 28/04/22 24/04/23 18/03/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
SHANXI C&Y PHARMACEUTICAL GROUP CO.,LTD. Stock ShanXi C&Y Pharmaceutical Group Co.,LTD.
-3.53% 311M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.85% 709B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.14% 595B
JOHNSON & JOHNSON Stock Johnson & Johnson
-2.09% 367B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.60% 334B
ABBVIE INC. Stock AbbVie Inc.
+5.07% 289B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.45% 239B
NOVARTIS AG Stock Novartis AG
+9.24% 211B
ROCHE HOLDING AG Stock Roche Holding AG
-3.48% 203B
AMGEN INC. Stock Amgen Inc.
+8.48% 171B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300254 Stock
  4. Financials ShanXi C&Y Pharmaceutical Group Co.,LTD.